This study is testing a combination of two treatments, a NY-ESO-1 Peptide vaccine and Toripalimab-tpzi, for women with advanced (Stage III or IV) ovarian cancer that has not responded well to platinum-based chemotherapy. The vaccine is given first to help prepare the body's immune system, followed by Toripalimab-tpzi, which is an anti-PD-1 therapy. Researchers want to see if this combination can prevent the cancer from growing or spreading (progression-free survival) over two years. You may be eligible if you are a woman aged 18 or older with this type of ovarian cancer. The study is currently recruiting 24 participants.

Study design

This is an open-label, single-arm study, meaning all 24 participants will receive the same treatment, and everyone involved will know which treatment is being given. It is a Phase II study.

What's involved

The NY-ESO-1 Peptide vaccine is given subcutaneously (under the skin) with the first two doses two weeks apart, and then three more doses. Toripalimab-tpzi is given intravenously (into a vein) every three weeks, starting with the second vaccine dose.

Compensation

Not stated in the trial record.

Follow-up

The study will measure how long participants live without their cancer progressing for at least two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.